cagrilintide vs MET-097i

NCT03856047 · Phase 2 · completed

The trial randomized participants to five active doses, a pooled placebo, and an active liraglutide comparator arm, with quadruple-blinding (participant, care provider, investigator, and outcomes assessor all masked) and roughly 100 participants per arm. The primary endpoint, percent change in body weight at 26 weeks, is the regulator-accepted physiological measure for obesity trials, and every cagrilintide dose showed a statistically significant weight-loss advantage over placebo (p-values ranging from 0.0002 to <.0001), so the primary comparison was clearly met in the favorable direction.

NCT06712836 · Phase 2 · completed

The study randomized 239 participants to MET097 or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical outcome of body-weight change at Week 28. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

NCT06897202 · Phase 2 · completed

The trial randomly assigned 133 participants to MET097 or placebo and was double-blinded, with percent change in body weight as the primary clinical endpoint. However, because no primary efficacy results are available, it is not possible to determine whether the endpoint was met.

Figures from conference coverage of the ADA 2026 presentation; weight change is from baseline, not placebo-adjusted, and no significance testing was reported for the weight endpoint. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.